Valerio Therapeutics (XPAR:ALVIO) Growth Rank: 2 (As of Sep. 15, 2026) — Near Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XPAR:ALVIO Valerio Therapeutics XPAR:ALVIO
28 GF Score
Price €0.67
GF Value €0.07
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Valerio Therapeutics Growth Rank?

Valerio Therapeutics XPAR:ALVIO -2.90% 28 Growth Rank is 2 as of Sep. 15, 2026, which is at its 10-year median of 2.00. GuruFocus rates XPAR:ALVIO with a GF Score™ of 28/100 and a GF Value™ of €0.07 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Valerio Therapeutics has the Growth Rank of 2.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Valerio Therapeutics Growth Rank Related Terms

XPAR:ALVIO vs VRTX, REGN, MRNA: Growth Rank Comparison

For the Biotechnology subindustry, Valerio Therapeutics's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Valerio Therapeutics Growth Rank vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Valerio Therapeutics's Growth Rank distribution charts can be found below:

* The bar in red indicates where Valerio Therapeutics's Growth Rank falls into.


XPAR:ALVIO
28GF Score
Valerio Therapeutics XPAR:ALVIO
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Growth Rank →
What does a Growth Rank of 2 mean?
Valerio Therapeutics (XPAR:ALVIO) has a Growth Rank of 2 as of Sep. 15, 2026. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Valerio Therapeutics and its competitors. This is near median its historical median of 2.00. Over the past decade, Valerio Therapeutics' Growth Rank has ranged from 1.00 to 6.00.
Is Valerio Therapeutics' Growth Rank too high?
Valerio Therapeutics' current Growth Rank of 2 is near median its 10-year median of 2.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 6.00. Overall, Valerio Therapeutics has a GF Score™ of 28/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Valerio Therapeutics' Growth Rank compare to VRTX and REGN?
Valerio Therapeutics' Growth Rank of 2 can be compared against companies in the Biotechnology industry. Historically, Valerio Therapeutics' own Growth Rank has ranged from 1.00 to 6.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Growth Rank for a Biotechnology company?
A good Growth Rank depends on the Biotechnology industry context. However, Growth Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Growth Rank mean?
A high Growth Rank can signal that a stock is expensive relative to its fundamentals. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Valerio Therapeutics and its competitors. Valerio Therapeutics's current Growth Rank is 2, which is near median its own 10-year median of 2.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Valerio Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Valerio Therapeutics (XPAR:ALVIO) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.07, compared to a current price of €0.67 — trading 857.1% above its estimated fair value. The current Growth Rank is 2, which is near median its 10-year median of 2.00. Valerio Therapeutics' overall GF Score™ is 28/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Growth Rank calculated?
Growth Rank is calculated from a company's financial statements. For Valerio Therapeutics (XPAR:ALVIO), the current Growth Rank is 2 as of Sep. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Valerio Therapeutics (XPAR:ALVIO) Overvalued in 2026?

Based on GuruFocus' analysis, Valerio Therapeutics stock appears to be overvalued. The current stock price of €0.67 is trading 857.1% above its estimated GF Value™ of €0.07. GuruFocus considers Valerio Therapeutics to be Significantly Overvalued.

Key valuation signals for XPAR:ALVIO:

  • Growth Rank: 2 (near median its 10-year median of 2.00)
  • GF Value™: €0.07 vs. price of €0.67 (857.1% above fair value)
  • GF Score™: 28/100 with 6 warning signs

No single metric tells the full story. See the XPAR:ALVIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Valerio Therapeutics Business Description

Other Exchanges 0NWK:UKC4X:Germany
Address 49, Boulevard du General, Martial Valin, Paris, FRA, 75015
Valerio Therapeutics is a clinical-stage biotechnology company developing drug candidates using three proprietary platforms: the PlatON platform, DecoyTAC, and the V-Body platform, generating single-domain therapeutic antibodies. The Company is focused on bringing early-stage first-in-class or disruptive compounds from translational research to clinical proof-of-concept, a value-creating inflection point appealing to potential partners. Its pipeline includes Metabolic Diseases, Immunology & Inflammatory.
28GF Score

Get the complete analysis for XPAR:ALVIO

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.67
Price
€0.07
GF Value